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ABSTRACT (197 words) 
 
Objectives To determine the risk of uveitis and inflammatory bowel disease (IBD) in 
psoriatic arthritis (PsA) patients compared to the general population and patients with 
psoriasis. 
 
Methods A cohort study using data from the UK Clinical Practice Research Datalink between 
1998 and 2014. Incident PsA patients aged 18-89 years were identified and matched to a 
cohort of patients with psoriasis and a general population cohort. The incidence of uveitis, 
all IBD, Crohn’s disease and ulcerative colitis was calculated for each study cohort and 
adjusted relative risks (RRadj) were calculated using conditional Poisson regression. 
 
Results 6,783 incident cases of PsA were identified with a median age of 49 years. The risk 
of uveitis was significantly higher in the PsA cohort than in the general population and 
psoriasis cohorts (RRadj 3.55, CI952.21-5.70 and RRadj 2.13, CI951.40-3.24 respectively). A 
significant increase was observed for Crohn’s disease (RRadj 2.96 CI951.46-6.00 and RRadj 3.60 
CI951.83-7.10) but not for ulcerative colitis (RRadj 1.30 CI950.66-2.56 and RRadj 0.98 CI950.50-
1.92). 
 
Conclusions 
In a primary care-based incidence cohort of patients with psoriatic arthritis there were 
substantial risks of developing uveitis and/or Crohn’s disease, but not ulcerative colitis, 
when compared to the general population and psoriasis controls. 
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INTRODUCTION 
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis which has been reported to affect 
between 10 and 40% of individuals with psoriasis.[1] In the majority of patients, PsA presents 
after, or synchronously with, the onset of psoriasis. PsA is well recognised to be progressive 
and may result in severe disability, reduced quality of life and work disability.[2, 3] Patients 
with PsA can often suffer from multiple comorbidities, resulting in increased morbidity and 
mortality.  
 
Uveitis and inflammatory bowel disease (IBD) are known to be associated with 
spondyloarthritis,[4] however there is limited information on the prevalence and incidence of 
these conditions in patients with PsA and current estimates and study designs vary. Recent 
Danish and Taiwanese nationwide cohort studies, using administrative data, have reported 
an increased risk of uveitis associated with psoriatic disease.[5, 6] The Danish study 
demonstrated a bidirectional association, with psoriasis and PsA patients having an 
increased risk of uveitis and patients with uveitis having an increased risk of psoriasis and 
PsA, suggesting a shared pathogenic pathway.[5] Another study, using the same Danish data 
source, has reported an increased risk of Crohn’s disease and ulcerative colitis amongst 
patients with psoriasis and PsA,[7] as have two studies using data from US Health Claims 
databases,[8, 9] and one looking at PsA using data from an Israeli healthcare database.[10] A 
further study analysing data on 174,476 women participating in a US Nurses’ Health Study, 
however, reported an increased risk of Crohn’s disease in patients with psoriasis and/or PsA 
but not an increased risk of ulcerative colitis.[11] 
 
This study aimed to determine the risks of uveitis and IBD in patients with PsA in the United 
Kingdom (UK) and compare these with the risks in a matched cohort of psoriasis patients 
without PsA and a general population cohort. 
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METHODS 
A cohort study was conducted using data from the Clinical Practice Research Datalink 
(CPRD), which is generally representative of the UK population[12] and contains anonymised 
primary care medical records for ~15 million individuals.  
 
The study period was from 1-Jan-1998 until 31-Dec-2014. A cohort of incident PsA patients 
were identified in the CPRD who were 18-89 years at diagnosis and had ≥1 year of up-to-
standard (UTS) data contribution prior to the diagnosis date. Cases of PsA were matched at 
a 1:4 ratio to two randomly selected cohorts based on date of PsA diagnosis (their index 
date), year of birth, sex and general practice: the first matched cohort (general population 
cohort) included patients with no psoriasis, no PsA and no other inflammatory arthritis 
diagnoses, and the second cohort (psoriasis cohort) included patients with psoriasis but no 
diagnosis of PsA or other inflammatory arthritis. Patients in the comparator cohorts were 
assigned the index date of the matched case and were required to have ≥1 year of UTS data 
prior to their index date. All patients were followed from the index date until the date they 
were no longer eligible for the cohort or were diagnosed with the outcome of interest. 
Patients in the general population and psoriasis cohorts who developed psoriasis or PsA 
respectively after the index date had their person-time contribution censored the day 
before the diagnosis date.  
 
The outcomes of interest were uveitis and inflammatory bowel disease (IBD). Diagnoses 
were identified based on Read codes and IBD was categorised as ‘Crohn’s disease’, 
‘ulcerative colitis’ and ‘other/unspecified’. A full description of the methods can be found in 
the Online Supplement.  
 
Statistical analyses 
The incidence of uveitis, all IBD, Crohn’s disease and ulcerative colitis was calculated for 
each of the study cohorts. For each outcome, crude and adjusted relative risks (RR) were 
calculated using conditional Poisson regression to compare the risk in the PsA cohort with 
the psoriasis and general population cohorts. The adjusted models accounted for smoking 
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status, body mass index and psoriasis severity on the index date. Analyses were performed 
using R 3.3.0 (R Core Team, 2017).  
 
RESULTS 
We identified 6,783 eligible incident cases of PsA that were matched to 27,132 psoriasis 
patients and 27,132 patients from the general population. The median age at PsA diagnosis 
was 49 years (IQR 39-59). The baseline patient characteristics for each cohort are shown in 
Table 1. The mean duration of follow-up post index date was similar in all three cohorts at 
approximately 5.5 years. The baseline prevalence of uveitis was 2.07 times higher in the PsA 
cohort than the general population (CI951.63-2.64).  
 
The median age at incident uveitis and ulcerative colitis was lower in the PsA cohort than 
psoriasis and general population cohorts (Table 2). The incidence and risk of uveitis was 
significantly higher in the PsA cohort than in the general population and psoriasis cohorts 
(RRadj 3.55, CI952.21-5.70 and RRadj 2.13, CI951.40-3.24) (Table 3). The incidence of all IBD was 
higher among patients with PsA and when looking at Crohn’s disease and ulcerative colitis 
separately, a significant increase was observed for Crohn’s (RRadj 2.96 CI951.46-6.00 and RRadj 
3.60 CI951.83-7.10 for general population and psoriasis cohorts respectively) but not for 
ulcerative colitis (RRadj 1.30 CI950.66-2.56 and RRadj 0.98 CI950.50-1.92). Of interest, current 
smokers had a higher incidence of Crohn’s disease than ex- or non-smokers but the 
numbers were too small to be meaningful (data not shown). 
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DISCUSSION 
This UK population-based study identified over a three-fold and two-fold increase in the risk 
of uveitis in patients with PsA when compared to the general population and patients with 
psoriasis respectively. A significant increase in risk was also observed for Crohn’s disease 
among patients with PsA but this was not found for ulcerative colitis.   
 
The increase in risk of uveitis associated with PsA, observed in our study, is in line with 
Danish and Taiwanese nationwide cohort studies.[5, 6] The incidence rates of uveitis in our 
study, however, were approximately 50% higher than in the Danish cohorts and lower than 
the Taiwanese cohorts which may be related to differences in methods of data collection. 
Genetic factors may also play a role, given the close association between HLA-B27 and acute 
anterior uveitis,[13] although the background prevalence of HLA-B27 is lower in Taiwan than 
in the UK.[14]  Nonetheless, a three-fold increase in risk of uveitis compared to the general 
population is clinically meaningful in terms of prospectively managing and informing 
patients of potential relevant co-morbidities. Furthermore, the risk appears more associated 
with PsA than with psoriasis, with the latter showing a similar baseline prevalence and 
incidence of uveitis to the general population. The baseline prevalence in the PsA cohort in 
our study is in line with an Irish study which included patients with ≤1 year PsA disease 
duration and reported a prevalence of uveitis of 1.55%[15] but is considerably lower than the 
9.09% reported in an Italian study which also included newly diagnosed patients with <1 
year disease duration.[16]  
 
The increased risk observed between PsA and Crohn’s disease, but not ulcerative colitis, is in 
line with a study by Li et al., using data from the Nurses’ Health study in the United 
States.[11] The majority of other studies to date, however, have identified an increased risk 
for both Crohn’s and ulcerative colitis, although many do report a higher magnitude of risk 
for Crohn’s than ulcerative colitis.[7, 9] 
 
There are genes in risk loci common to psoriasis, PsA and Crohn’s disease such as IL12B, 
5q31, IL23R and IL2/IL21 that may explain our findings.[17] Dysbiosis leading to an 
upregulated Th17 driven immune response in a genetically susceptible host is another 
potential common pathogenic pathway.[18] Indeed a recent study reported a specific 
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dysbiosis in patients with spondylitis and a history of IBD.[19] Lifestyle factors such as 
smoking may also have an important role, especially considering that smoking is a known 
risk factor for Crohn’s whilst smoking is associated with a lower risk of developing ulcerative 
colitis.[20] It is likely that an interaction of all these factors is important and worthy of study 
in larger datasets.  
 
Strengths of our study include its population-based nature, the large number of PsA 
patients, previous validation of the codes used to identify psoriasis and PsA, inclusion of 
both a psoriasis and general-population matched comparator group and the length of 
follow-up after PsA diagnosis. The inclusion of only incident PsA patients was an advantage 
for looking at the temporal relationship, however one challenge when studying PsA, 
particularly when looking at comorbidities and risk factors, is disentangling pre-clinical PsA 
from psoriasis and/or delayed diagnosis.[21] It is therefore possible that some patients within 
the psoriasis only group may have actually had PsA and this could potentially have elevated 
the incidence rates in this group. In addition, as PsA is likely to develop some time before a 
patient visits their GP, it is also possible that some patients identified as having prevalent 
disease, prior to their PsA diagnosis, may have developed the comorbidity of interest after 
the initial onset of PsA, but before a formal diagnosis was made, which would result in an 
underestimate of the incidence rates. Although unlikely for uveitis, assessment/detection 
bias could also have played a role for mild IBD cases, with PsA patients being likely to visit 
their healthcare professionals more regularly than those in the comparator groups. 
Unfortunately, the absence of data on tumour necrosis factor-alpha inhibitor (TNFi) therapy 
in the CPRD meant it was not possible to explore the effect of PsA therapy on the incidence 
of uveitis and IBD. 
 
The results of our study demonstrate an increased risk of developing uveitis and Crohn’s 
disease in patients with PsA that in addition to pointing to shared genetic and pathogenic 
mechanisms has important implications for surveillance and management. More precise 
information on the estimated risk of these particular comorbidities can be shared with 
patients, alongside advice on lifestyle factors such as smoking, the latter of which in addition 
to its association with Crohn’s disease[20] has also been shown to have a negative effect on 
long-term PsA outcome.[22]  
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Table 1 Baseline characteristics of the PsA, psoriasis and general population cohorts  
 PsA Psoriasis  
cohort 
General 
population cohort 
 N % N % N % 
N 6,783  27,132  27,132  
Sex (% male) 3,327 49.05 13,308 49.05 13,308 49.05 
Median age*, years (IQR) 49 (39-59) 49 (39-59) 49 (39-59) 
Mean follow-up post index, years (SD) 5.8 (4.1) 5.5 (4.1) 5.5 (4.1) 
Mean duration of psoriasis,* years (SD) 11.3 (10.9) 11.8 (10.6) --- --- 
Uveitis prevalenceϮ, ¥ 100 1.47 205 0.76 193 0.71 
Inflammatory bowel disease prevalenceϮ 51 0.75 323 1.19 249 0.92 
 Crohn’s diseaseϮ 16 0.24 122 0.45 95 0.35 
 Ulcerative colitisϮ 24 0.35 150 0.55 127 0.47 
*  on index date     
Ϯ  ≥1 diagnosis recorded in the CPRD on or before the index date 
¥ Of all the uveitis records identified, 71.5% were anterior, 1.5% were posterior, 0.3% were panuveitis and for 
26.7% the anatomic subtype was unknown. There was one case of posterior uveitis in the PsA cohort and 6 
cases in both the psoriasis and general population cohorts.  
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Table 2 Incidence of uveitis and IBD in the PsA, psoriasis and general population cohorts 
 Cases Median age 
at diagnosis 
(IQR) 
  Person 
years 
Incidence rate per 
10,000 person years 
(CI95) 
Uveitis      
General population 46† 55.0  (41.0-62.0) 146,738 3.13 (2.30-4.18) 
Psoriasis 74‡ 55.0  (48.0-65.0) 145,482 5.09 (3.99-6.39) 
PsA 42¥ 47.0  (40.0-58.0) 38,678 10.86 (7.83-14.68) 
      
Inflammatory bowel disease (All)      
General population 67 55.0  (43.5-67.5) 146,345 4.58  (3.55-5.81) 
Psoriasis 67 53.0  (44.0-68.0) 144,793 4.63  (3.59-5.88) 
PsA 30 51.5  (42.0-60.0) 39,077 7.68  (5.18-10.96) 
Crohn’s disease      
General population 25 50.0  (43.0-68.0) 146,345 1.71  (1.11-2.52) 
Psoriasis 22 50.5  (44.0-62.0) 144,793 1.52   (0.95-2.30) 
PsA 16 49.5  (33.0-56.5) 39,077 4.09   (2.34-6.65) 
Ulcerative colitis      
General population 35 57.0  (44.0-66.0) 146,345 2.39    (1.67-3.33) 
Psoriasis 38 60.5  (46.0-71.0) 144,793 2.62    (1.86-3.60) 
PsA 11 54.0  (46.0-61.0) 39,077 2.81    (1.41-5.04) 
† 31 anterior, 15 subtype unknown   ‡ 50 anterior, 1 panuveitis, 23 subtype unknown   ¥ 29 anterior, 1 
panuveitis, 12 subtype unknown        
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Table 3 Risk of uveitis and inflammatory bowel disease in patients with PsA compared with patients in the general population and patients 
with psoriasis 
Comorbidity PsA compared with a general population cohort 
(no PsA and no psoriasis) 
PsA compared with a psoriasis cohort  
(psoriasis and no PsA) 
 Unadjusted Adjusted† Unadjusted Adjusted‡ 
 RR CI95 P RR CI95 P RR CI95 P RR CI95 P 
Uveitis 3.83 2.45-5.99 <0.0001 3.55 2.21-5.70 <0.0001 2.17 1.46-3.22 <0.0001 2.13 1.40-3.24 <0.001 
 
All inflammatory bowel disease 1.95 1.28-2.98 <0.0001 1.90 1.21-3.00 0.0056 1.71 1.13-2.61 <0.01 1.71 1.12-2.61 <0.05 
- Crohn’s disease 3.08 1.64-5.80 <0.0001 2.96 1.46-6.00 0.0025 3.55 1.83-6.88 <0.0001 3.60 1.83-7.10 <0.001 
- Ulcerative colitis 1.30 0.68-2.46 0.43 1.30 0.66-2.56 0.44 1.08 0.58-2.02 0.80 0.98 0.50-1.92 0.96 
† adjusted for smoking status and body mass index (in the 3 months prior to the index date) ‡ adjusted for smoking status and body mass index (in the 3 months prior to the 
index date) and psoriasis disease severity on the index date   
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